2024
Adaption and National Validation of a Tool for Predicting Mortality from Other Causes Among Men with Nonmetastatic Prostate Cancer
Justice A, Tate J, Howland F, Gaziano J, Kelley M, McMahon B, Haiman C, Wadia R, Madduri R, Danciu I, Leppert J, Leapman M, Thurtle D, Gnanapragasam V. Adaption and National Validation of a Tool for Predicting Mortality from Other Causes Among Men with Nonmetastatic Prostate Cancer. European Urology Oncology 2024, 7: 923-932. PMID: 38171965, DOI: 10.1016/j.euo.2023.11.023.Peer-Reviewed Original ResearchVeterans Health AdministrationCharlson Comorbidity IndexNon-prostate cancer mortalityProstate cancer mortalityNonmetastatic prostate cancerComorbidity indexCancer mortalityProvider estimationProstate cancerHealth AdministrationUS Veterans Health AdministrationElectronic health record-based toolsYear of diagnosisRisk of deathObservational cohortMedian ageNonmetastatic cancerPredicting MortalityC-statisticHispanic ethnicityTreatment groupsMortalityCancerNational validationAge
2018
Impact of HIV on Clinical Presentation and Outcomes of Individuals with Multiple Myeloma
Giri S, Wong E, Rose M, Wadia R, Park L, Justice A, Neparidze N. Impact of HIV on Clinical Presentation and Outcomes of Individuals with Multiple Myeloma. Blood 2018, 132: 3162. DOI: 10.1182/blood-2018-99-115633.Peer-Reviewed Original ResearchVeterans Aging Cohort StudyMultiple myelomaEM diseaseUninfected patientsClinical characteristicsLytic lesionsOutcome of MMRisk of MMImpact of HAARTRole of HAARTStage 3 diseaseSymptomatic multiple myelomaTime of diagnosisAggressive clinical courseAging Cohort StudyClinical outcome dataCourse of diseasePlasma cell disordersDurie-Salmon stageVeterans Health AdministrationImpact of HIVSignificant differencesStage 1High rateStage 2